What Rambam does

Rambam AG is a Swiss-based biotech venture studio founded in 2021 and headquartered in Zug, Switzerland. Operating as part of the Expert Systems accelerator platform, the company forms, funds, and supports early-stage drug discovery companies, claiming an expedient two-year timeline from company formation to early clinical candidates through ultra-efficient seed and Series A capital deployment. Its portfolio includes NeurOdys Therapeutics (neurodegenerative disorders, Amsterdam), Polku Therapeutics Oy (Parkinson's and Alzheimer's, Helsinki), and Eilean Therapeutics LLC (hematological cancers). Rambam has co-funded over 20 programs and companies alongside institutional partners including OrbiMed Advisors, BGV, NEA, NLC Health Ventures, and Innovestor Life Science Fund, with Torrey Pines Investment serving as its venture capital parent.

The core technology offering is an AI-enabled drug discovery platform supported by computer-aided drug design, rational program design, and execution capabilities. Rambam has direct access to two integrated technology stacks: the Expert Systems accelerator platform (a vertically integrated AI-powered drug discovery platform covering program selection, prioritization, design, execution, and market positioning) and Molsoft's rational design and virtual discovery platform (structure prediction, cheminformatics, molecular visualization). Together these platforms have produced named preclinical candidates including FLT3 and BCL2 inhibitors for Eilean Therapeutics and a best-in-class M-Pro/3CL candidate for COVID-19. Rambam's therapeutic focus spans oncology, inflammation, immunology, cardiometabolic, neurology, and infectious diseases.

Rambam's revenue model is venture studio returns from portfolio company equity realized through successful exits (categorized as licensing and royalties), rather than commercial product sales. The go-to-market relies on direct investment, co-funding with established venture firms, strategic partnerships with portfolio companies, and conference-driven business development (notably BIO-Europe 2024). With a lean operating team of 1-10 employees, Rambam leverages a core group of seasoned industrial experts, program managers, and functional area specialists across Switzerland, Portugal, Germany, the Netherlands, Finland, and the US. No public pricing, ARR, or revenue figures are disclosed.

Name

Rambam

Legal name

Rambam AG

Website

https://rambam.ch

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Rambam AG is a Swiss-based biotech venture studio and part of the Expert Systems accelerator platform that forms and funds early-stage drug discovery companies. It leverages AI-enabled computer-aided drug design to advance portfolio programs from formation to clinical candidates within approximately two years.

Ownership category

akta.pro rank

Product category

Biotech Venture Studio

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Investment Advice (6282)

akta.pro primary industry

Corporate Venture Capital (CVC) (FSANAAAF)

Keywords

• Venture studio services
• Drug discovery platform
• Biotech accelerator programs
• AI drug design
• Preclinical development support

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Venture Studio Returns: Returns generated from portfolio company equity through successful exits. Rambam supports expedient 2-year progress from company formation to early clinical candidates with ultra efficient seed and series A capital, targeting low attrition and successful biotech outcomes.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Rambam AG is a venture studio that supports early-stage biotech companies by providing capital, an AI-enabled drug discovery platform, and expert guidance from a global network of pharmaceutical and academic partners. The studio identifies undervalued, science-driven preclinical assets and co-funds new biotech ventures, accelerating their path toward clinical proof-of-concept. Portfolio companies include NeurOdys Therapeutics, Polku Therapeutics, and Eilean Therapeutics, spanning neurology, antibody-based therapies, and oncology.

Product overview

Rambam AG is a Swiss-based venture studio and part of the Expert Systems accelerator platform for breakthrough drug discovery and development. The company's offering consists of a venture studio model that supports expedient 2-year progress from company formation to early clinical candidates through ultra-efficient seed and Series A capital. The platform is AI-enabled and supported by computer-aided drug design capabilities including the Expert Systems Accelerator Platform (a vertically integrated AI-powered drug discovery platform) and Molsoft's rational design tools. Rambam's portfolio includes portfolio companies such as NeurOdys Therapeutics (neurodegenerative disorders), Polku Therapeutics Oy (Parkinson's and Alzheimer's), and Eilean Therapeutics (hematological cancers), all leveraging these technology platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• NeurOdys Therapeutics Rambam-backed portfolio company developing an innovative drug for neurological disorders, with a focus on Charcot-Marie-Tooth disease type 1A (CMT1A). It is a privately held biotech company co-founded and supported through Rambam's venture studio model.
• Polku Therapeutics Oy Rambam-backed portfolio company developing a new class of antibody-based drugs for cancer and inflammatory diseases. It is a Finland-based biotech co-founded with Torrey Pines Investment and supported through Rambam's venture studio model.
• Eilean Therapeutics LLC Rambam-backed portfolio company developing a new generation of oncology drugs targeting previously undruggable cancer targets. It is a U.S.-based biotech co-founded and supported through Rambam's venture studio model.
• Expert Systems Accelerator Platform Accelerator platform partnership supporting Rambam's portfolio companies with access to drug discovery acceleration technology, providing infrastructure and resources for early-stage biotech development.
• Molsoft Rational Design and Virtual Discovery Platform Rational design and virtual discovery platform partnership providing Rambam's portfolio companies with drug design technology access for computational drug discovery and structural biology applications.

Quantifiable outcome

• 2-year timeline from company formation to early clinical candidates
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Expert Systems InccoreStrategic or Co-development PartnerPart of the Expert Systems accelerator platform for breakthrough drug discovery and development. Provides direct access to Expert Systems' technology consulting platform, bringing together biotech venture funding and rational program design and execution to translate scientific insights into novel medicines.
• NeurOdys TherapeuticscoreStrategic or Co-development PartnerCutting-edge biotechnology startup co-founded by Rambam AG and NLC Health Ventures, headquartered in Amsterdam. Focused on developing transformative treatments for neurodegenerative disorders using small molecule therapies.
• Polku Therapeutics OycoreStrategic or Co-development PartnerHelsinki-based startup focused on discovering innovative treatments for neurodegenerative diseases, particularly Parkinson's and Alzheimer's. Rambam provides strategic collaboration to accelerate research efforts, identify drug candidates and mitigate risks.
• Molsoft LLCcoreTechnology or IntegrationLeading provider of tools, databases and consulting services in structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and rational drug design. Their rational design platform has led to discovery of best-in-class candidates for Eilean Therapeutics.
• Eilean Therapeutics LLCcoreStrategic or Co-development PartnerPortfolio company targeting escape mutations in hematological cancers with first and best in class medicines. Funded by i2020 Accelerator and OrbiMed Advisors, utilizing Molsoft and Expert Systems design platforms.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Atlas Venture: A Boston-based venture firm that builds biotech companies from inception, providing operating support and seed/Series A capital. Directly comparable to Rambam's model of company formation, program execution, and syndication with larger VCs.
• Apollo Therapeutics: A UK-based venture builder that translates academic research into therapeutic companies with pharma backing. Comparable to Rambam's role bridging biotech venture funding with therapeutic program execution.
• Flagship Pioneering: The original and largest biotech venture creation firm, originating companies like Moderna. Rambam's venture-studio model that forms and funds multiple biotechs around a shared technology platform closely mirrors Flagship's Genesis Engine approach.
• Curie.Bio: A biotech venture studio that provides capital, operating support, and shared infrastructure to launch new therapeutic companies. Highly comparable in structure to Rambam's venture studio model, though with a US focus.
• Medicxi: A European biotech asset-centric investment firm that creates and incubates companies through a venture builder model. Directly comparable to Rambam as another European-based biotech origination platform.
• Accelerator Life Science Partners: An early-stage biotech investment and company formation firm that creates and operates portfolio companies. Comparable to Rambam in forming and supporting therapeutic-focused biotech startups.
• Droia Ventures: A specialist biotech venture builder focused on oncology and genetic disease. Comparable to Rambam's portfolio focus areas (especially Eilean Therapeutics' oncology work) and venture creation approach.

Broad incumbents

• Recursion Pharmaceuticals: A tech-enabled drug discovery company using AI and high-throughput biology for therapeutic programs. An adjacent AI-driven drug discovery platform that competes for partnerships and attention in the same space Rambam's Expert Systems/Molsoft stack targets.
• BridgeBio Pharma: A larger public biotech that originated multiple subsidiaries targeting genetic diseases, similar in spirit to Rambam's multi-company approach. A broader incumbent that operates its own clinical pipeline rather than a pure venture studio.

Others

• OrbiMed Advisors: A leading global healthcare-dedicated investment firm that is a co-funding partner of Rambam. Listed as a co-investor in Rambam's venture studio and as a financial backer of Eilean Therapeutics, providing capital rather than direct competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/rambam-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rambam